• Mashup Score: 0

    ARLINGTON, Texas — Data show that the commonly used metric of 10,000 steps per day is associated with improvements to overall and CV health, but the number likely is an overestimate and benefits vary by age and sex, according to a speaker.The concept of 10,000 steps per day was created by a Japanese marketing company in 1964 to sell a pedometer, called “Manpo-kei,” which

    Tweet Tweets with this article
    • ICYMI: "The media likes to talk about this magic number of 10,000 steps per day," German said. "Interestingly enough, this number came about with no scientific evidence for backing" @ASPCardio #ASPC2023 @DrGermanMD @UChicagoMed #cardiotwitter https://t.co/1eFmxLHSfx

  • Mashup Score: 0

    ARLINGTON, Texas — Data show that the commonly used metric of 10,000 steps per day is associated with improvements to overall and CV health, but the number likely is an overestimate and benefits vary by age and sex, according to a speaker.The concept of 10,000 steps per day was created by a Japanese marketing company in 1964 to sell a pedometer, called “Manpo-kei,” which

    Tweet Tweets with this article
    • ICYMI: "The media likes to talk about this magic number of 10,000 steps per day," German said. "Interestingly enough, this number came about with no scientific evidence for backing" @ASPCardio #ASPC2023 @DrGermanMD @UChicagoMed #cardiotwitter https://t.co/1eFmxLHSfx

  • Mashup Score: 2

    ARLINGTON, Texas — Data show that the commonly used metric of 10,000 steps per day is associated with improvements to overall and CV health, but the number likely is an overestimate and benefits vary by age and sex, according to a speaker.The concept of 10,000 steps per day was created by a Japanese marketing company in 1964 to sell a pedometer, called “Manpo-kei,” which

    Tweet Tweets with this article
    • Data show that the commonly used metric of 10,000 steps per day is associated with improvements to overall and CV health, but the number likely is an overestimate and benefits vary by age and sex @ASPCardio #ASPC2023 @DrGermanMD @UChicagoMed #cardiotwitter https://t.co/1eFmxLHSfx

  • Mashup Score: 0

    ARLINGTON, Texas — In this Healio video exclusive, Healio | Cardiology Today Editorial Board Member Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, discusses how anatomical and functional testing both have a role in cardiac diagnosis. Michos, who is associate professor of medicine and director of women’s cardiovascular health research at Johns Hopkins Medicine, participated in a

    Tweet Tweets with this article
    • In this Healio video exclusive, Healio | Cardiology Today Editorial Board Member @ErinMichos, discusses how anatomical and functional testing both have a role in cardiac diagnosis at #ASPC2023 @ASPCardio @CiccaroneCenter @HopkinsMedicine #Cardiotwitter https://t.co/riqqcZHLgV

  • Mashup Score: 4

    ARLINGTON, Texas — Familial hypercholesterolemia is common, underdiagnosed and undertreated, and one complementary approach to improve its diagnosis could include leveraging the blood donation system, according to a speaker. It is estimated that about one in 250 people have familial hypercholesterolemia (FH), an autosomal-dominant disorder that is common across race and ethnic groups and is

    Tweet Tweets with this article
    • ICYMI: “Between 70% and 90% of people in the U.S. that have FH are not diagnosed,” Khera said. “That is a call to arms against something that is very treatable, that has a lot of morbidity. We must do better.” @dramitkhera @UTSWNews @ASPCardio #ASPC2023 https://t.co/OfzNEPr60O

  • Mashup Score: 2

    Home > CardioNerds > Lp(a) Therapeutics in Development – New Medications in the Armamentarium for ASCVD? Elevated lipoprotein (a) [Lp(a)] is an established risk factor for atherosclerotic cardiovascular disease (ASCVD), as demonstrated in several epidemiological, genome-wide association, and Mendelian randomization studies (1-3). However, to date, there are no available therapies that lead to a substantial reduction in Lp(a) and no clinical trial data to support that lowering Lp(a) reduces adverse cardiovas

    Tweet Tweets with this article
    • Lp(a) Therapeutics in Development‼️ Article in @mydocwire on @RonBlankstein’s talk at #ASPC2023 🔗 https://t.co/oMLsCSFZMs https://t.co/mPaluTv9ei https://t.co/9WhkRTJgGk

  • Mashup Score: 5

    Home > CardioNerds > Lp(a) Therapeutics in Development – New Medications in the Armamentarium for ASCVD? Elevated lipoprotein (a) [Lp(a)] is an established risk factor for atherosclerotic cardiovascular disease (ASCVD), as demonstrated in several epidemiological, genome-wide association, and Mendelian randomization studies (1-3). However, to date, there are no available therapies that lead to a substantial reduction in Lp(a) and no clinical trial data to support that lowering Lp(a) reduces adverse cardiovas

    Tweet Tweets with this article
    • The @Cardionerds review news from the @ASPCardio 2023 Congress on lipoprotein (a) therapeutics, an evolving class of agents being explored in patients with atherosclerotic cardiovascular diseases. https://t.co/nu7VBceRkW #ASPC2023 #Cardionerds https://t.co/l0Y8ghpSCW

  • Mashup Score: 0

    ARLINGTON, Texas — Familial hypercholesterolemia is common, underdiagnosed and undertreated, and one complementary approach to improve its diagnosis could include leveraging the blood donation system, according to a speaker. It is estimated that about one in 250 people have familial hypercholesterolemia (FH), an autosomal-dominant disorder that is common across race and ethnic groups and is

    Tweet Tweets with this article
    • ICYMI: “Between 70% and 90% of people in the U.S. that have FH are not diagnosed,” Khera said. “That is a call to arms against something that is very treatable, that has a lot of morbidity. We must do better.” @dramitkhera @UTSWNews @ASPCardio #ASPC2023 https://t.co/OfzNEPr60O

  • Mashup Score: 0

    ARLINGTON, Texas — Familial hypercholesterolemia is common, underdiagnosed and undertreated, and one complementary approach to improve its diagnosis could include leveraging the blood donation system, according to a speaker. It is estimated that about one in 250 people have familial hypercholesterolemia (FH), an autosomal-dominant disorder that is common across race and ethnic groups and is

    Tweet Tweets with this article
    • #FamilialHypercholesterolemia is common, underdiagnosed and undertreated, and one complementary approach to improve its diagnosis could include leveraging the blood donation system @dramitkhera @UTSWNews @ASPCardio #ASPC2023 https://t.co/OfzNEPr60O

  • Mashup Score: 4

    ARLINGTON, Texas — An accurate BP measurement is essential to properly diagnose and manage hypertension, yet most providers do not have time to follow the guideline-recommended steps, according to a speaker.Clinic or office BP measurements are one of the most common medical procedures; however, many providers do not follow a standardized approach or do not use clinically validated devices,

    Tweet Tweets with this article
    • ICYMI: Office BP measurements are one of the most common medical procedures; however, many providers do not follow a standardized approach or do not use clinically validated devices, leading to faulty BP measurements @ASPCardio #ASPC2023 #cardiotwitter https://t.co/GOpfmSwup3